Breaking Finance News

Clovis Oncology Inc (NDAQ:CLVS) target price raised to $125.00, reported today by Gabelli

Yesterday Clovis Oncology Inc (NDAQ:CLVS) traded 2.01% higher at $95.87. The company’s 50-day moving average is $87.18 and its 200-day moving average is $67.07. The last stock close price is up 5.84% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 1,287,020 shares of the stock were exchanged, down from an average trading volume of 1,968,820

Clovis Oncology Inc (NDAQ:CLVS) had its target price raised to $125.00 by Gabelli in a report released 7/7/2017. The new target price indicates a possible upside of 0.30% based on the company's last stock close price.

See Chart Below

Clovis Oncology Inc (NDAQ:CLVS)

Clovis Oncology Inc has a 52 week low of $16.58 and a 52 week high of $99.45 The company’s market cap is currently $0.

In addition to Gabelli reporting its target price, a total of 8 firms have reported on the stock. The consensus target price is $17.50 with 2 firms rating the stock a strong buy, 0 firms rating the stock a buy, 6 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Clovis Oncology Inc (NDAQ:CLVS)

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.